Similar articles

• [Differences between oral antidiabetics].

  Bleskestad IH, Birkeland KI. Bleskestad IH, et al. Tidsskr Nor Laegeforen. 2003 Mar 20;123(6):808-9. Tidsskr Nor Laegeforen. 2003. PMID: 12693123 Norwegian. No abstract available.
• [Clinical trial of AY4166].

  Kikuchi M. Kikuchi M. Nihon Rinsho. 1997 Nov;55 Suppl:164-70. Nihon Rinsho. 1997. PMID: 9434462 Review. Japanese. No abstract available.
• [Achieving better control of blood sugar--understanding of oral hypoglycemic agents according to their characteristics in pharmacological action mechanism (discussion)].

  Kawamori R, Kadowaki T, Ishida H. Kawamori R, et al. Nihon Rinsho. 2004 Apr;62(4):831-9. Nihon Rinsho. 2004. PMID: 15106356 Japanese. No abstract available.
• Pharmacodynamic aspects of two sulphonylurea derivatives glipizide and glibenclamide.

  Artini D, Abbiati R, Orsini G, Parenti MA, Bloch K, Daturi S, Mandelli V. Artini D, et al. Diabetologia. 1973 Sep:311-6. doi: 10.1007/BF01218440. Diabetologia. 1973. PMID: 4204091 No abstract available.
• Nateglinide.

  Dunn CJ, Faulds D. Dunn CJ, et al. Drugs. 2000 Sep;60(3):607-615; discussion 616-7. doi: 10.2165/00003495-200060030-00007. Drugs. 2000. PMID: 11030470 Review.